Sheena Jonathan sold $2.9M of NTRA

Sheena Jonathan sold 9,150 shares of Natera, Inc. (NTRA) at an average of $315.66 ($308.40–$320.90, $2.89M total) across 10 trades on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Aug 8, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 8, 2026, 1:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but this disclosure alone does not change Natera’s fundamentals or near-term earnings outlook.

02

Market read

The only new information is the reported insider sale size, timing, and execution details; no new guidance, trial, or regulatory event is included.

03

What to watch

10b5-1 plans are often pre-scheduled for liquidity or diversification, so the sale may not reflect new information; also, the price range is broad, suggesting multiple executions rather than a single timing bet.

Relevance 5/10Novelty 3/10Timing: filed after-hours on 2026-08-07, reflecting trades dated 2026-08-07

Background

The article is an SEC Form 4 insider transaction for Natera, Inc., reporting a director’s open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera director Sheena Jonathan sold about $2.89M of NTRA shares via an open-market sale under a pre-arranged 10b5-1 plan on 2026-08-07.

Expected impact

Likely limited, with any impact more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 plan, and it provides no new company-specific performance, guidance, or regulatory development.

Market effects

Minimal. Insider sales in a single biotech/genomics name typically do not reset sector expectations without accompanying fundamentals.

None indicated.

None indicated.

Counterpoint

A large director sale could be interpreted as a signal of reduced confidence, even if executed under a 10b5-1 plan.

Key entities

  • Natera, Inc.

    Company whose director insider sale is disclosed on Form 4.

  • Sheena Jonathan

    Director who sold 9,150 shares in multiple trades on 2026-08-07.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.